Prosecution Insights
Last updated: April 19, 2026
Application No. 18/699,871

AN INJECTABLE POLYHYDROXYALKANOATE MICROSPHERE AND A PREPARATION METHOD THEREOF

Non-Final OA §103
Filed
Apr 09, 2024
Examiner
GEMBEH, SHIRLEY V
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BEIJING JOYINERA BIOMATERIAL TECHNOLOGY CO., LTD.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
2y 8m
To Grant
97%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
1014 granted / 1606 resolved
+3.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
42 currently pending
Career history
1648
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
39.0%
-1.0% vs TC avg
§102
18.2%
-21.8% vs TC avg
§112
15.1%
-24.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1606 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-14 are pending and under examination in this office action. Information Disclosure Statement Receipt is acknowledged of the Information Disclosure Statement filed 4/4/25; 1/8/25 and 4/9/25. The Examiner has considered the references cited therein to the extent that each is a proper citation. Please see the attached USPTO Form 1449. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Yano et al. (US 2003/019443). Yano teaches preparation of polyhydroxyalkanoate (i.e. PHA, see 0067) microspheres (see same) comprising dissolving the PHA in an organic solvent (see 0065, 0087) wherein the organic solvent is chloroform (see 0087, as required by instant claim 3) to obtain an oil phase (see abstract, claim 30) wherein the PHA is from 0.01-60% depending on the PHA (see 0393)with a molecular weight of the PHA is from 1-10 (see 0124), dissolving hyaluronic acid in water (see 0398) with a concentration of 0.01% (see 0398), stirred and evaporated (as required by instant claim 1, see 0088), with a mixing ratio of 1:1-100 (see 0348 as required by instant claim 2), with a magnetic stirrer (see 0358) at a stirring rate from 50-3,000 rpm (see 0409, as required by instant claim 8) at a temperature from 15-40 degrees (see 0296, as required by instant claim 11). With regards to the molecular weight (as required by instant claims 1, 4-5), Yano teaches that the molecular weight of PHA can range from 1000-10million, preferable 1 to 5 (see 0124), therefore it is within the purview of the skilled artisan to use the appropriate PHA for the intended invention. Yano also teaches stirring from 1 minute to 24 hours, therefore one of ordinary skill in the art would have a good reason to pursue the known options for the preparation and determine the particular conventional working condition through experimentation (as required by instant claims 9-10). Jano also teaches the particle size is from 2-200 µM, therefore it is within reason that the particle size is less than 60 since the molecular weight of PHA is within the cited range. However Yano did not per se teach the freeze drying at temperatures from -80- -20. Nonetheless teaches the preparation using lyophilization (see 0381). Accordingly, the person of ordinary skill in the art, having the laboratory walls would have been motivated to attain the known advantages of freeze drying and lyophilization to and choose between the methods to get a better overall indication of efficacy. Accordingly, the invention as claimed is prima facie obvious. As optimization of parameters is routine practice that would be obvious to a person of ordinary skill. It would havebeen customary for an artisan of ordinary skill to determine the particle size of the active ingredient in order to best achieve the desired results. Thus, absent some demonstration of unexpected results from the claimed parameters, this optimization of dosage amount would have been obvious at the time of applicant's invention. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHIRLEY V GEMBEH whose telephone number is (571)272-8504. The examiner can normally be reached M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHIRLEY V GEMBEH/Primary Examiner, Art Unit 1615 2/11/26
Read full office action

Prosecution Timeline

Apr 09, 2024
Application Filed
Feb 13, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599566
TITANIUM DIOXIDE FREE WHITE FILM COATING COMPOSITION, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594314
Process and Apparatus for Production of a Granular Cannabinoid Material Essentially Soluble in Aqueous Medium
2y 5m to grant Granted Apr 07, 2026
Patent 12582146
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR, BLOOD PRESSURE-LOWERING AGENT, AND BEVERAGES AND FOOD PRODUCTS
2y 5m to grant Granted Mar 24, 2026
Patent 12582689
USE OF TERPENOIDS IN THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
2y 5m to grant Granted Mar 24, 2026
Patent 12582690
Compositions for preventing or treating cancer comprising extracts of Rubus longisepalus var. tozawai (Nakai) T.B.Lee
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
97%
With Interview (+33.6%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 1606 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month